|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 8 (April 15), 1997:
pp. 2994-2998
Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma
By
James E. Wooldridge,
Zuhair Ballas,
Arthur M. Krieg, and
George J. Weiner
From the Iowa City Veterans Administration, the Department of Internal Medicine, and the Graduate Program in Immunology, The University of Iowa College of Medicine, Iowa City, IA.
 |
ABSTRACT |
Bacterial DNA and synthetic oligodeoxynucleotides containing the CpG motif (CpG ODN) can activate various immune cell subsets, including natural killer cells and macrophages. We evaluated whether the combination of CpG ODN and antitumor monoclonal antibody is effective at preventing tumor growth in an immunocompetent murine lymphoma model. CpG ODN-activated murine splenocytes induced lysis of tumor targets more effectively than unactivated splenocytes. These effector cells were also superior to unactivated splenocytes or cells activated with a control methylated ODN at inducing antibody-mediated lysis of 38C13 murine lymphoma cells. In vivo, CpG ODN alone had no effect on survival of mice inoculated with 38C13 cells. However, a single injection of CpG ODN enhanced the antitumor response to antitumor monoclonal antibody therapy. Ninety percent of mice treated with monoclonal antibody alone developed tumor compared with 20% of mice treated with antibody and CpG ODN. These antitumor effects were less pronounced when treatment consisted of an identical ODN containing methylated CpG dinucleotides. A single dose of CpG ODN appeared to be as effective as multiple doses of interleukin-2 at inhibiting tumor growth when combined with antitumor monoclonal antibody. We conclude that immunostimulatory CpG ODN can enhance antibody dependent cellular cytotoxicity and warrant further evaluation as potential immunotherapeutic reagents in cancer.
| |
INTRODUCTION |
RECENT STUDIES have demonstrated that bacterial DNA, but not vertebrate DNA, can have significant immunostimulatory effects on B cells,1-3 natural killer (NK) cells,4-6 and macrophages.7 NK cells can be activated by the nucleic acid fraction of attenuated mycobacterial cells (Bacillus-Calmette-Guerin [BCG])8 and by DNA synthesized in 30mer and 45mer lengths from the BCG genome. Such activated NK cells produce interferon- (IFN-) and show enhanced NK cytolytic activity.6 NK cells activated by bacterial DNA have in vivo antitumor activity as well.8 Recent studies demonstrate that macrophages are activated by the bacterial DNA that is internalized after phagocytosis.7 These immunostimulatory effects are due, at least in part, to sequences containing unmethylated CpG dinucleotides, because the effects are abolished by cytosine methylation.3 In addition, synthetic oligodeoxynucleotides containing CpG motifs (CpG ODN) also can enhance NK and macrophage activity.4,7 Vertebrate DNA, but not bacterial DNA, exhibits CpG suppression and extensive methylation of cytosines in CpG dinucleotides. We therefore have postulated that lymphocyte activation by unmethylated CpG dinucleotides may have evolved as a mechanism by which the immune response to microbial infection could be enhanced.3
The immune response normally involves the integrated production of a variety of cytokines that work in concert both locally and systemically. At the cellular level, CpG ODN induce secretion of interleukin-6 (IL-6), IL-12, and IFN-2,4,9 but not IL-2. In unfractionated spleen cultures, NK activation by CpG ODN is unaffected by removal of B cells or T cells, but decreases markedly upon neutralization of IL-12, tumor necrosis factor- (TNF-), and IFN-.4 Interestingly, highly purified NK cells are not activated by CpG ODN.4,9 It therefore appears that stimulation of an additional population of cells, such as monocytes/macrophages, by CpG ODN is important in achieving NK activation.
The mechanisms responsible for CpG ODN-induced immune activation are under intensive investigation. Stacey et al7 have found that bacterial DNA and CpG ODN can activate transcription factor nuclear factor- B, which subsequently leads to induction of other genes involved in inflammation.7 Preliminary data from our laboratory also suggest that DNA containing the CpG dinucleotide functions by inducing generation of reactive oxygen species.10
Both NK cells and monocytes/macrophages participate in antibody-dependent cellular cytotoxicity (ADCC). Activation of NK cells with cytokines can enhance ADCC in vitro and the efficacy of monoclonal antibody (MoAb) therapy in vivo.11 Enhancement of tumor immunity may be most effective if agents are used that can orchestrate the immune response, including cytokine production and cellular activation, in a manner that reflects physiological responses. CpG ODN are such agents. The current studies were designed to evaluate whether CpG ODN can enhance ADCC in vitro and improve the therapeutic efficacy of antitumor MoAb therapy in vivo.
| |
MATERIALS AND METHODS |
Tumor model.
The 38C13 murine B-cell lymphoma model has been used extensively in studies of antitumor MoAb therapy.11-14 38C13 cells were grown in RPMI 1640 supplemented with 100 U/mL of penicillin and streptomycin, 2-mercaptoethanol, and 10% fetal bovine serum (Hyclone Laboratories, Logan, UT) that was heat inactivated at 56°C (complete media). Cells were used in log-phase growth. The idiotype expressed by the surface IgM of 38C13 serves as a highly specific tumor antigen. The IgG2a anti-idiotype MoAb designated MS11G6 has been previously described14,15 and is referred to as antitumor MoAb. It was purified from cell culture supernatant by affinity chromatography using protein A and used in both the in vitro and in vivo assays.
Oligodeoxynucleotide preparation.
Phosphorothioate oligodeoxynucleotides were kindly provided by Genta (San Diego, CA) or purchased from Oligos etc (Wilsonville, OR). An immunostimulatory CpG oligodeoxynucleotide (with the sequence 5' TCT CCC AGC GTG CGC CAT 3') was selected for further study when it was found to have a significant effect on murine NK cells with little effect on murine B cells. This CpG oligodeoxynucleotide (henceforth referred to as CpG ODN) at concentrations ranging from 1.25 to 20 µg/mL also had no effect on the in vitro proliferation of 38C13 cells (data not shown). It should be noted that this sequence is also antisense to the human Bcl-2 gene and has partial homology to the antisense to mouse Bcl-2 gene. The control oligodeoxynucleotide (control methylated ODN) had an identical sequence, but contained methylcytosines in the CpG motifs (see Fig 1). Lipopolysaccharide levels were assessed by the Limulus assay and were always less than 12.5 ng/mg of ODN.
View larger version (7K):
[in this window]
[in a new window]
| Fig 1.
Sequences of CpG ODN and methylated control ODN. Underlined cytosines in the control ODN were methylated.
|
|
In vitro chromium release assay.
A standard chromium release assay was used to detect cytotoxicity. Spleens of naive 6- to 8-week-old C3H/HeN mice were homogenized, and erythrocytes were removed by hypo-osmolar lysis with a solution containing 0.15 mol/L NH4Cl, 1.0 mmol/L KHCO3 , 0.1 mmol/L Na2EDTA at a pH of 7.4. B cells were removed by anti-Ig selection using a biotinylated goat antimouse Ig (Sigma, St Louis, MO) and avidin-coated micromagnetic beads eluted over a magnetic column (Miltenyi Biotech, Auburn, CA). The eluted cells were washed with media and cultured in complete media alone or media supplemented with CpG ODN, control methylated ODN, or 500 U/mL of recombinant human IL-2 (Chiron, Emeryville, CA) for 24 to 72 hours before use as effector cells. Target cells (38C13) were labeled with 200 µCi of Cr51 (Amersham Life Sciences, Arlington Heights, IL) for 1 hour and washed three times. Cells were divided and incubated at 4°C for 30 minutes in complete media or media supplemented with 5 µg/mL antitumor MoAb before distribution into 96-well V-bottom culture plates (Costar, Cambridge, MA) at the desired cellular concentrations. Effector cells were added at the desired effector to target ratios. Plates were incubated for 4 hours at 37°C in a humidified environment containing 5% CO2 and supernatants evaluated by counting. Nonspecific release of Cr51 (percent release from target cells incubated for 4 hours without effector cells or MoAb) was less than 20% for all experiments. Samples were run in triplicate, and the percentage of lysis was determined.
In vivo tumor therapy.
38C13 cells grow rapidly and consistently in syngeneic, immunocompetent C3H/HeN mice. Female C3H/HeN mice, obtained from Harlan-Sprague-Dawley (Indianapolis, IN) and housed in the Animal Care Unit at the University of Iowa, were used at 6 to 8 weeks of age. Mice were inoculated with 2,500 38C13 tumor cells intraperitoneally (IP), and therapy with CpG or control methylated ODN, IL-2, and antitumor MoAb was administered IP beginning 2 days later as indicated. CpG ODN and control methylated ODN were used at a dose of 300 µg per mouse because pilot studies demonstrated systemic effects at that dose. Survival was determined, and significance with respect to time to death was assessed using Cox regression analysis.16 Mice were observed daily for signs of toxicity including level of activity, ruffled fur, diarrhea, and general appearance.
| |
RESULTS |
CpG ODN enhances NK cytolytic activity and ADCC in vitro.
We first assessed the NK cytolytic activity of CpG ODN-stimulated effector cells in vitro using NK-sensitive YAC-1 cells as targets as previously reported.4 Effector cells stimulated with IL-2 served as a control. Unstimulated effector cells and effector cells stimulated with 2.5 µg/mL of control methylated ODN induced minimal lysis, whereas significant lysis was mediated by effector cells stimulated with 2.5 µg/mL of CpG ODN or IL-2 at a concentration of 500 U/mL (data not shown). We then explored whether CpG ODN enhances ADCC in vitro. As illustrated in Fig 2, lysis of 38C13 cells was minimal when unstimulated effector cells or effector cells stimulated with control methylated ODN were used. IL-2-activated effector cells were capable of mediating lysis. This was enhanced further when antitumor MoAb was added. Similar, although less profound effects were noted when CpG ODN-stimulated effector cells were used. Thus, CpG ODN enhanced ADCC mediated by antitumor MoAb, but not to the same degree as IL-2.
View larger version (18K):
[in this window]
[in a new window]
| Fig 2.
CpG ODN or IL-2 prestimulation of mononuclear splenocytes in combination with MoAb enhances lysis of 38C13 cells in vitro. Splenocytes were activated as described in the Materials and Methods. Target 38C13 cells were labeled with chromium-51 for 1 hour followed by incubation with MoAb (5 µg/mL) for 30 minutes at 4°C. Effector cells and target cells were plated at a 25:1 effector-target ratio and chromium release was determined.
|
|
CpG ODN enhances antitumor therapy with antitumor MoAb.
Previous studies have demonstrated that antitumor MoAb in the 38C13 model has a moderate antitumor effect when administered in large doses (100 µg) 4 hours after inoculation of the mice with tumor. The antitumor effect of MoAb is limited in this rapidly growing tumor model when therapy is delayed for greater than 24 to 48 hours after tumor inoculation.14,15,17 We therefore assessed whether treatment with CpG ODN allows for more effective MoAb therapy when treatment with MoAb is delayed beyond the time when MoAb is usually effective (Fig 3). Mice were inoculated with 2,500 38C13 cells and divided into groups of 10. Mice received no therapy (group 1), treatment with a single IP injection of 300 µg CpG ODN on day 2 (group 2), therapy with a single injection of 50 µg antitumor MoAb IP on day 3 (group 3), or both CpG ODN and antitumor MoAb (group 4). No toxicity was noted in any group. All mice in the control group (group 1) died within 24 days. Mice that received CpG ODN alone (group 2) had slightly improved survival, but all developed lymphoma and died within 34 days. Mice treated with antitumor MoAb alone had prolonged survival when compared with untreated mice, but only 1 of 10 mice achieved long-term survival. In contrast, 8 of 10 mice treated with CpG ODN followed by antitumor MoAb survived without evidence of tumor. The survival of this group was highly significant when compared with the other groups (v CpG ODN alone, P < .001; v MoAb alone, P = .0109).
View larger version (11K):
[in this window]
[in a new window]
| Fig 3.
CpG ODN and MoAb are more effective than MoAb alone in vivo at preventing death from tumor. Immunocompetent C3H mice were inoculated with 2,500 tumor cells IP on day 0. Therapy consisted of ( ) no ODN or MoAb, ( ) MoAb alone, ( ) CpG ODN alone, or ( ) CpG ODN and MoAb. CpG ODN (300 µg) was administered IP on day 2, and MoAb (50 µg) was administered on day 3. Each group contained 10 mice. Curves depict percent survival over 60 days. No mice living at day 60 developed tumor, and all survived more than 5 months. No toxicity was observed in any group.
|
|
Comparison of antitumor therapy with CpG ODN and antitumor MoAb to therapy with IL-2 and antitumor MoAb.
IL-2 has been shown to enhance the efficacy of anti-idiotype MoAb therapy in the 38C13 model. IL-2 is most effective when administered repeatedly.11 We therefore compared in vivo therapy of antitumor MoAb with CpG ODN to therapy with MoAb and IL-2 (Fig 4). Mice in the IL-2 groups received 50,000 U IL-2 twice daily for 3 days. Mice received no therapy (group 1), treatment with a single IP injection of 300 µg CpG ODN on day 2 (group 2), therapy with a single injection of 50 µg antitumor MoAb IP on day 3 (group 3), both CpG ODN and antitumor MoAb (group 4), IL-2 alone (group 5), or IL-2 and MoAb (group 6). CpG DNA plus antitumor MoAb therapy resulted in long-term survival of 70%, whereas IL-2 plus antitumor MoAb resulted in long-term survival of only 40%. This difference did not reach statistical significance (P = .20).
View larger version (22K):
[in this window]
[in a new window]
| Fig 4.
Therapy with CpG ODN and MoAb enhances survival as effectively as therapy with IL-2 and MoAb. Immunocompetent C3H mice were inoculated with 2,500 tumor cells IP on day 0. Therapy consisted of MoAb alone, CpG ODN alone, IL-2 alone, IL-2 and MoAb, or CpG ODN and MoAb. IL-2 (50,000 U) was administered IP twice daily on days 2, 3, and 4. CpG ODN (300 µg) was administered IP on day 2, and MoAb (50 µg) was administered on day 3 as in Fig 3. Each group contained 10 mice. Curves depict the percentage of survival over 60 days. No mice living at day 60 developed tumor, and all survived more than 5 months. No toxicity was observed in any group. () No therapy; () MoAb on day 3; () CpG ODN on day 2; ( ) IL-2 on days 2, 3, and 4; ( ) IL-2 on days 2, 3, and 4 and MoAb on day 3; () CpG ODN on day 2 and MoAb on day 3.
|
|
Comparison of antitumor therapy with CpG ODN and antitumor MoAb to therapy with control methylated ODN and antitumor MoAb.
In vitro studies suggested the control methylated ODN had little effect on enhancement of ADCC. However, it was possible other mechanisms, such as antisense activity, contributed to the antitumor effect seen in vivo with CpG ODN and MoAb. We therefore evaluated therapy in vivo with MoAb and control methylated ODN in parallel with the IL-2 study outlined above. Control methylated ODN added little to the therapeutic efficacy of MoAb alone (control methylated ODN and MoAb v MoAb alone, P = .12) (Fig 5) in contrast to the studies outlined in Fig 3 where therapy with MoAb and CpG ODN was more effective than therapy with MoAb alone.
View larger version (22K):
[in this window]
[in a new window]
| Fig 5.
Therapy with CpG ODN and MoAb enhances survival more effectively than therapy with control methylated ODN and MoAb. Immunocompetent C3H mice were inoculated with 2,500 tumor cells IP on day 0. Therapy consisted of MoAb alone, control methylated ODN alone, CpG ODN alone, control methylated ODN and MoAb, or CpG ODN and MoAb. Mice were followed for tumor development, toxicity, and survival. Each group contained 10 mice. Curves depict percent survival over 60 days. No mice living at day 60 developed tumor, and all survived more than 5 months. No toxicity was observed in any group. () No therapy; () MoAb on day 3; () control methylated ODN on day 2; ( ) CpG ODN on day 2; () control methylated ODN on day 2 and MoAb on day 3; () CpG ODN on day 2 and MoAb on day 3.
|
|
| |
DISCUSSION |
B-cell lymphomas are among the most sensitive tumors to MoAb-based immunotherapy. Agents known to enhance NK activity, such as IL-2, have been shown to enhance the antitumor effects of antilymphoma MoAb. We used a well-established lymphoma model to evaluate whether the antitumor effects of MoAb can be enhanced by CpG ODN that induce NK activation. There was clear synergy between CpG ODN and antitumor MoAb in this model and the most likely explanation for this finding is enhanced ADCC. It is unlikely that the CpG ODN has a direct effect on tumor cells, given tumor proliferation was not inhibited in vitro by CpG ODN and only minimal therapeutic benefit was seen in the group treated with CpG ODN alone. An alternative explanation is that the CpG ODN-induced production of cytokines rendered the tumor cells more sensitive to ADCC.
These effects were largely eliminated when an ODN containing identical sequences but having methylated cytosines in the CpG motif was used. Because the 5-methyl cytosine base substitutions actually increase the affinity for hybridization to complementary mRNA, this finding demonstrates that the antitumor effect of this ODN cannot be attributed solely to an antisense mechanism.
Anecdotal reports of tumor regression after systemic bacterial infection have been observed for centuries. Experimental antitumor therapy with heat-inactivated bacteria was reported by Dr William Coley18 in the 1890s. Dr Coley's original attempt to use bacteria as an antitumor agent involved the use of live cultures of streptococci.18 This resulted in tumor regression, but proved to be toxic with the first patient almost dying of erysipelas. Subsequent studies by Coley involved a mixture of heat-killed Streptococci and Serratia (then known as Bacillus prodigiosus).19 It was this preparation that is now known as Coley's toxin. Much of the antitumor activity of Coley's toxin is currently attributed to endotoxin. A number of cytokines induced by endotoxin (such as TNF- and IFN-) have been produced in recombinant form and have been shown to have antitumor activity.20 However, it is curious to note that Coley's original success was with an organism that does not produce endotoxin. It is possible bacterial DNA with its unmethylated CpG motifs played a role in the antitumor effects seen in Coley's original preparation. Whether the responses seen by Dr Coley were related to the immunostimulatory effects of streptococcal DNA, the data presented above indicate that motifs found in bacterial DNA can have antitumor effects, particularly when used with other agents such as MoAb.
A number of important questions remain to be answered. The mechanisms by which bacterial DNA and CpG ODN interact with the cell surface of immune effector cells are internalized and induce activation signals that lead to NK cell and macrophage stimulation need to be clarified. It will also be important to understand more thoroughly how different subsets of immune cells respond to CpG ODN and what aspects of that response are related directly to CpG ODN stimulation or indirectly to cytokines such as IL-6, IL-12, or IFN. Although we observed no toxicity in vivo, the toxicity profile of CpG ODN will require definition. We detected no direct effect of the CpG ODN on 38C13 lymphoma cells; however, it is possible the CpG ODN induced changes in the tumor cells that rendered them more sensitive to MoAb therapy. These studies therefore need to be confirmed in another tumor model and using other CpG ODN.
As we learn more about the immune system, it is becoming obvious that an effective antitumor immunotherapy will need to integrate several aspects of the immune system, including establishment of appropriate cytokine profiles, modification of tumor immunogenicity, enhancement of tumor antigen recognition, and appropriate effector cell expansion and activation. The studies outlined above demonstrate immunostimulatory DNA in general, and CpG ODN in particular, may have a role to play in the development of such a therapy.
| |
FOOTNOTES |
Submitted September 9, 1996;
accepted December 4, 1996.
Supported in part by a grant from the University of Iowa Cancer Center. J.E.W. is supported by National Institutes of Health Grant No. T32HL07344, and A.M.K. is supported by a career development award from the Department of Veterans Affairs.
Address reprint requests to George J. Weiner, MD, C32K GH, The University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
We thank Yina Hsing and Wendy Rasmussen for technical assistance and Charles Davis for assistance with statistical analysis.
| |
REFERENCES |
1.
Messina JP,
Gilkeson GS,
Pisetsky DS:
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA.
J Immunol
147:1759,
1991[Abstract]
2.
Klinman DM,
Yi A-K,
Beaucage SL,
Conover J,
Krieg AM:
CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-.
Proc Natl Acad Sci USA
93:2879,
1996[Abstract/Free Full Text]
3.
Krieg AM,
Yi A-K,
Matson S,
Waldschmidt TJ,
Bishop GA,
Teasdale R,
Koretzky GA,
Klinman DM:
CpG motifs in bacterial DNA trigger direct B-cell activation.
Nature
374:546,
1995[Medline]
[Order article via Infotrieve]
4.
Ballas ZK,
Rasmussen WL,
Krieg AM:
Induction of natural killer activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
J Immunol
157:1840,
1996[Abstract]
5.
Yamamoto S,
Yamamoto T,
Shimada S,
Kuramoto E,
Yano O,
Kataoka T,
Tokunaga T:
DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth.
Microbiol Immunol
36:983,
1992[Medline]
[Order article via Infotrieve]
6.
Yamamoto S,
Kuramoto E,
Shimada S,
Tokunaga T:
In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG.
Jpn J Cancer Res
79:866,
1988[Medline]
[Order article via Infotrieve]
7.
Stacey KJ,
Sweet MJ,
Hume DA:
Macrophages ingest and are activated by bacterial DNA.
J Immunol
157:2116,
1996[Abstract]
8.
Shimada S,
Yano O,
Tokunaga T:
In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG.
Jpn J Cancer Res
77:808,
1986[Medline]
[Order article via Infotrieve]
9.
Cowdery JS,
Chace JH,
Yi A-K,
Krieg AM:
Bacterial DNA induces NK cells to produce interferon gamma in vivo and increases the toxicity of lipopolysaccharide.
J Immunol
156:4570,
1996[Abstract]
10.
Yi A-K,
Klinman DM,
Martin TL,
Matson S,
Krieg AM:
Rapid immune activation by CpG motifs in bacterial DNA.
J Immunol
157:5394,
1996[Abstract]
11.
Berinstein N,
Levy R:
Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
J Immunol
139:971,
1987[Abstract]
12.
Maloney DG,
Kaminski MS,
Burowski D,
Haimovich J,
Levy R:
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro.
Hybridoma
4:191,
1986
13.
Starnes CO,
Carroll WL,
Campbell MJ,
Houston LL,
Apell G,
Levy R:
Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
J Immunol
141:333,
1988[Abstract]
14.
Weiner GJ,
Kaminski MS:
Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
J Immunol
142:343,
1989[Abstract]
15.
Weiner GJ,
Kaminski MS:
Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
J Immunol
144:2436,
1990[Abstract]
16.
Cox DR:
Regression models and life-tables (with discussion).
J R Stat Soc Series B
34:187,
1972
17.
Kaminski MS,
Kitamura K,
Maloney DG,
Campbell MJ,
Levy R:
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
J Immunol
136:1123,
1986[Abstract]
18.
Coley WB:
The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases.
Am J Med Sci
105:487,
1893
19.
Coley WB:
Treatment of inoperable malignant tumors with the toxins of Erysipelas and the Bacillus prodigiosus.
Am J Med Sci
108:183,
1894
20.
Wiemann B,
Starnes CO:
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective.
Pharmacol Ther
64:529,
1994[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. OLBERT, A. J. SCHRADER, C. SIMON, A. DALPKE, P. BARTH, R. HOFMANN, and A. HEGELE
In Vitro and In Vivo Effects of CpG-Oligodeoxynucleotides (CpG-ODN) on Murine Transitional Cell Carcinoma and on the Native Murine Urinary Bladder Wall
Anticancer Res,
June 1, 2009;
29(6):
2067 - 2076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et al.
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clin. Cancer Res.,
October 15, 2007;
13(20):
6168 - 6174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood,
September 15, 2005;
106(6):
1911 - 1923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdorfer, L. Muhlenhoff, S. E. Blackwell, M. Wagner, H. Poeck, E. Hartmann, R. Jox, T. Giese, B. Emmerich, S. Endres, et al.
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides
Clin. Cancer Res.,
February 15, 2005;
11(4):
1490 - 1499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg, H. Kim, M. McCauley, E. M. Hessel, P. Sims, D. C. Fisher, L. M. Nadler, R. L. Coffman, and A. S. Freedman
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity
Blood,
January 15, 2005;
105(2):
489 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Elias, J. Flo, R. A. Lopez, J. Zorzopulos, A. Montaner, and J. M. Rodriguez
Strong Cytosine-Guanosine-Independent Immunostimulation in Humans and Other Primates by Synthetic Oligodeoxynucleotides with PyNTTTTGT Motifs
J. Immunol.,
October 1, 2003;
171(7):
3697 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-J. Chiang, Y.-L. Ye, W.-L. Chen, Y.-L. Lee, N.-Y. Hsu, and B.-L. Chiang
Ribavirin or CpG DNA Sequence-Modulated Dendritic Cells Decrease the IgE Level and Airway Inflammation
Am. J. Respir. Crit. Care Med.,
September 1, 2003;
168(5):
575 - 580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. van Ojik, L. Bevaart, C. E. Dahle, A. Bakker, M. J. H. Jansen, M. J. van Vugt, J. G. J. van de Winkel, and G. J. Weiner
CpG-A and B Oligodeoxynucleotides Enhance the Efficacy of Antibody Therapy by Activating Different Effector Cell Populations
Cancer Res.,
September 1, 2003;
63(17):
5595 - 5600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar
CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma
Clin. Cancer Res.,
August 1, 2003;
9(8):
3105 - 3114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rieger and T. J. Kipps
CpG Oligodeoxynucleotides Enhance the Capacity of Adenovirus-mediated CD154 Gene Transfer to Generate Effective B-Cell Lymphoma Vaccines
Cancer Res.,
July 15, 2003;
63(14):
4128 - 4135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wang and A. M. Krieg
Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation
Int. Immunol.,
February 1, 2003;
15(2):
223 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Weigel, N. Nath, P. A. Taylor, A. Panoskaltsis-Mortari, W. Chen, A. M. Krieg, K. Brasel, and B. R. Blazar
Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
Blood,
December 1, 2002;
100(12):
4169 - 4176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Heckelsmiller, K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann
Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model
J. Immunol.,
October 1, 2002;
169(7):
3892 - 3899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug, S. Rothenfusser, G. Meinhardt, B. Emmerich, S. Endres, and G. Hartmann
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
J. Leukoc. Biol.,
July 1, 2002;
72(1):
83 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sfondrini, D. Besusso, M. T. Zoia, M. Rodolfo, A. M. Invernizzi, M. Taniguchi, T. Nakayama, M. P. Colombo, S. Menard, and A. Balsari
Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice
J. Immunol.,
July 1, 2002;
169(1):
151 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
Blood,
February 15, 2002;
99(4):
1320 - 1326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology,
January 1, 2002;
2002(1):
241 - 262.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Z. K. Ballas, A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner
Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs
J. Immunol.,
November 1, 2001;
167(9):
4878 - 4886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Blazar, A. M. Krieg, and P. A. Taylor
Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients
Blood,
August 15, 2001;
98(4):
1217 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hafner, R. Zawatzky, C. Hirtreiter, W. A. Buurman, B. Echtenacher, T. Hehlgans, and D. N. Mannel
Antimetastatic Effect of CpG DNA Mediated by Type I IFN
Cancer Res.,
July 1, 2001;
61(14):
5523 - 5528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdörfer, G. Hartmann, E. Racila, W. Jackson, L. Mühlenhoff, G. Meinhardt, S. Endres, B. K. Link, A. M. Krieg, and G. J. Weiner
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens
J. Leukoc. Biol.,
January 1, 2001;
69(1):
81 - 88.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Weiner
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
J. Leukoc. Biol.,
October 1, 2000;
68(4):
455 - 463.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. E. Guinness, J. L. Kenney, M. Reiss, and J. Lacy
Bcl-2 Antisense Oligodeoxynucleotide Therapy of Epstein-Barr Virus-associated Lymphoproliferative Disease in Severe Combined Immunodeficient Mice
Cancer Res.,
October 1, 2000;
60(19):
5354 - 5358.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. J. Klasa, M. B. Bally, R. Ng, J. H. Goldie, R. D. Gascoyne, and F. M. P. Wong
Eradication of Human Non-Hodgkin's Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide
Clin. Cancer Res.,
June 1, 2000;
6(6):
2492 - 2500.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. S. Waters, A. Webb, D. Cunningham, P. A. Clarke, F. Raynaud, F. di Stefano, and F. E. Cotter
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
May 9, 2000;
18(9):
1812 - 1823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hartmann, R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, et al.
Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo
J. Immunol.,
February 1, 2000;
164(3):
1617 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, F. Schneller, T. Sparwasser, T. Tretter, G. B. Lipford, H. Wagner, and C. Peschel
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
Blood,
February 1, 2000;
95(3):
999 - 1006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hartmann and A. M. Krieg
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells
J. Immunol.,
January 15, 2000;
164(2):
944 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-K. Yi, D. W. Peckham, R. F. Ashman, and A. M. Krieg
CpG DNA rescues B cells from apoptosis by activating NF{kappa}B and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway
Int. Immunol.,
December 1, 1999;
11(12):
2015 - 2024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Carpentier, L. Chen, F. Maltonti, and J.-Y. Delattre
Oligodeoxynucleotides Containing CpG Motifs Can Induce Rejection of a Neuroblastoma in Mice
Cancer Res.,
November 1, 1999;
59(21):
5429 - 5432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Iho, T. Yamamoto, T. Takahashi, and S. Yamamoto
Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN-{gamma} Production In Vitro
J. Immunol.,
October 1, 1999;
163(7):
3642 - 3652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, and J. Goldie
Progression to Androgen Independence Is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model
Clin. Cancer Res.,
October 1, 1999;
5(10):
2891 - 2898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hartmann, G. J. Weiner, and A. M. Krieg
CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
PNAS,
August 3, 1999;
96(16):
9305 - 9310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Miyake, A. Tolcher, and M. E. Gleave
Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model
Cancer Res.,
August 1, 1999;
59(16):
4030 - 4034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Elkins, T. R. Rhinehart-Jones, S. Stibitz, J. S. Conover, and D. M. Klinman
Bacterial DNA Containing CpG Motifs Stimulates Lymphocyte-Dependent Protection of Mice Against Lethal Infection with Intracellular Bacteria
J. Immunol.,
February 15, 1999;
162(4):
2291 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-M. Liu, S. E. Newbrough, S. K. Bhatia, C. E. Dahle, A. M. Krieg, and G. J. Weiner
Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor
Blood,
November 15, 1998;
92(10):
3730 - 3736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Redford, A.-K. Yi, C. T. Ward, and A. M. Krieg
Cyclosporin A Enhances IL-12 Production by CpG Motifs in Bacterial DNA and Synthetic Oligodeoxynucleotides
J. Immunol.,
October 15, 1998;
161(8):
3930 - 3935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Krieg, L. Love-Homan, A.-K. Yi, and J. T. Harty
CpG DNA Induces Sustained IL-12 Expression In Vivo and Resistance to Listeria monocytogenes Challenge
J. Immunol.,
September 1, 1998;
161(5):
2428 - 2434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-K. Yi, R. Tuetken, T. Redford, M. Waldschmidt, J. Kirsch, and A. M. Krieg
CpG Motifs in Bacterial DNA Activate Leukocytes Through the pH-Dependent Generation of Reactive Oxygen Species
J. Immunol.,
May 15, 1998;
160(10):
4755 - 4761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Weiner, H.-M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
PNAS,
September 30, 1997;
94(20):
10833 - 10837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract